Polymyxin B hemoperfusion in septic patients with acute myeloblastic and premyelocytic leukemia

2021 ◽  
Vol 10 ◽  
pp. 1
Author(s):  
Luigi De Simone ◽  
Katia Valentini ◽  
Francesca Maceri ◽  
Sabrina Cidin ◽  
Edoardo Benedetti ◽  
...  
Keyword(s):  
Polymyxin B ◽  
Polymyxin B Hemoperfusion

scholarly journals Effects of Polymyxin B Hemoperfusion on Septic Shock Patients Requiring Noradrenaline: Analysis of a Nationwide Administrative Database in Japan

2021 ◽  
pp. 1-6
Author(s):  
Kenji Fujimori ◽  
Kunio Tarasawa ◽  
Kiyohide Fushimi
Keyword(s):  
Septic Shock ◽  
Propensity Score ◽  
Propensity Score Matching ◽  
Polymyxin B ◽  
Administrative Database ◽  
Control Group ◽  
Continuous Hemodiafiltration ◽  
Significant Survival ◽  
Maximum Daily Dose ◽  
Polymyxin B Hemoperfusion

<b><i>Introduction:</i></b> Polymyxin B hemoperfusion (PMX) reduces endotoxin in septic shock patients’ blood and can improve hemodynamics and organ functions. However, its effects on the reduction of septic shock mortality are controversial. <b><i>Methods:</i></b> Using the Japanese diagnosis procedure combination database from April 2016 to March 2019, we identified adult septic shock patients treated with noradrenaline. This study used propensity score matching to compare the outcome between PMX-treated and non-treated patients. The primary endpoint was 28-day mortality, counting from the day of noradrenaline initiation. The secondary endpoints were noradrenaline-, ventilator-, and continuous hemodiafiltration (CHDF)-free days at day 28. <b><i>Results:</i></b> Of 30,731 eligible patients, 4,766 received PMX. Propensity score matching produced a matched cohort of 4,141 pairs with well-balanced patient backgrounds. The 28-day survival rate was 77.9% in the PMX group and 71.1% in the control group (<i>p</i> &#x3c; 0.0001). Median days of noradrenalin-, CHDF-, and ventilator-free days were 2 days (<i>p</i> &#x3c; 0.0001), 2 days (<i>p</i> &#x3c; 0.0001), and 6 days (<i>p</i> &#x3c; 0.0001) longer in the PMX group than in the control group, respectively. When stratified with the maximum daily dose of noradrenaline, the PMX group showed a statistically significant survival benefit in the groups with noradrenaline dose &#x3c;20 mg/day but not in the noradrenaline group dose ≥20 mg/day. <b><i>Conclusion:</i></b> Analysis of large Japanese databases showed that septic shock patients who received noradrenaline might benefit from PMX treatment.

Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis

Cytokine ◽  
2013 ◽  
Vol 61 (1) ◽  
pp. 84-89 ◽  
Author(s):  
Keiji Oishi ◽  
Yuka Mimura-Kimura ◽  
Taku Miyasho ◽  
Keisuke Aoe ◽  
Yoshiko Ogata ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Acute Exacerbation ◽  
Polymyxin B ◽  
Polymyxin B Hemoperfusion

scholarly journals More effective use of polymyxin-B hemoperfusion for nonoperation cases

Critical Care ◽  
2014 ◽  
Vol 18 (S2) ◽  
Author(s):  
M Yahata ◽  
Y Sakamoto ◽  
S Inoue ◽  
T Iwamura ◽  
R Fujita ◽  
...  
Keyword(s):  
Polymyxin B ◽  
Effective Use ◽  
Polymyxin B Hemoperfusion

scholarly journals Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level

JAMA ◽  
2018 ◽  
Vol 320 (14) ◽  
pp. 1455 ◽  
Author(s):  
R. Phillip Dellinger ◽  
Sean M. Bagshaw ◽  
Massimo Antonelli ◽  
Debra M. Foster ◽  
David J. Klein ◽  
...  
Keyword(s):  
Septic Shock ◽  
Polymyxin B ◽  
Endotoxin Level ◽  
Polymyxin B Hemoperfusion

Clinical Effects of Polymyxin B Hemoperfusion in Patients With Septic Shock Caused by Urinary Tract Infection

2018 ◽  
Vol 23 (1) ◽  
pp. 80-85 ◽  
Author(s):  
Yasushi Suzuki ◽  
Masahiro Kojika ◽  
Hisaho Sato ◽  
Yoshihiro Inoue ◽  
Shigeatsu Endo
Keyword(s):  
Septic Shock ◽  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Polymyxin B ◽  
Clinical Effects ◽  
Polymyxin B Hemoperfusion

Novel Insights into the Direct Removal of Endotoxin by Polymyxin B Hemoperfusion

2017 ◽  
Vol 44 (3) ◽  
pp. 193-197 ◽  
Author(s):  
Alexander D. Romaschin ◽  
Christina V. Obiezu-Forster ◽  
Hisataka Shoji ◽  
David J. Klein
Keyword(s):  
Whole Blood ◽  
Bovine Serum ◽  
Binding Capacity ◽  
Biological Fluids ◽  
Performance Testing ◽  
Polymyxin B ◽  
Direct Hemoperfusion ◽  
Human Whole Blood ◽  
Clinically Significant ◽  
Polymyxin B Hemoperfusion

Aim: To demonstrate the capacity of polymyxin B-direct hemoperfusion (PMX-DHP) column Toraymyxin® 20R (PMX-20R) in removing endotoxin (LPS) from perfused blood, serum and plasma. Methods: Endotoxin-spiked bovine serum or plasma was perfused in PMX-20R as per the recommended performance testing protocol. Samples were taken at various time points to assess the amount of endotoxin removed during a 4-h session. In another set of experiments, FITC-labelled LPS (FITC-LPS) was spiked into a pool of human whole blood, followed by perfusion with the spiked blood for 2 h in order to allow FITC-LPS to bind PMX-20R. The amount of LPS was extracted from the columns and the amount of specifically bound LPS was determined by fluorometry. Results: PMX-20R columns perfused with bovine serum or plasma had an average binding rate of 88%, equivalent to approximately 12 µg of LPS. When PMX-20R was perfused with human whole blood, the columns bound an average of 20 µg of FITC-LPS. Conclusion: PMX-20R can bind LPS in all the biological fluids tested. The calculated binding capacity of 12-20 µg LPS suggests that in septic cases where endotoxin is present in the circulation, PMX-20R is able to adsorb clinically significant levels of endotoxin.

scholarly journals Polymyxin B hemoperfusion: a mechanistic perspective

Critical Care ◽  
2014 ◽  
Vol 18 (3) ◽  
pp. 309 ◽  
Author(s):  
Claudio Ronco ◽  
David J Klein
Keyword(s):  
Polymyxin B ◽  
Polymyxin B Hemoperfusion
Sign in / Sign up

Export Citation Format

Share Document